CIRM Funded Clinical Trials

Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa

Disease Area:

Retinitis Pigmentosa

Investigator:

Institution:

Ray Therapeutics, INC

CIRM Grant:

CLIN2-17086 (Pre-Active)

Award Value:

$7,975,224.00

Trial Sponsor:

Ray Therapeutics, INC

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.